The US FDA has approved a new obesity drug, Zepbound, developed by Eli Lilly. This treatment, already used for diabetes, has shown significant effectiveness for weight loss.
Intended for obese or overweight people with associated health problems, and should be used in combination with exercise and a low-calorie diet. However, it may have side effects such as nausea and abdominal pain. The cost is $1,060 per month, which poses access problems for patients because obesity medications are often not reimbursed by health insurance in the United States. Eli Lilly is committed to working to ensure broader access to Zepbound.
This medication is part of a new generation of treatments that mimic a gastrointestinal hormone (GLP-1) that regulates appetite. Experts emphasize that these treatments must be taken long term to avoid regaining lost weight. Remember that in the United States, approximately 40% of adults are obese.
Pascal Lemontel
|